PDF下载 ( 117 KB)
Clinical study on phentolamine-mesilate combined diammonium-glycyrrhizinate in the treatment of chronic hepatitis gravis.
-
摘要: 观察酚妥拉明联合甘利欣治疗慢性重型肝炎的疗效。 30例慢性重型肝炎患者 ,随机分为治疗组和对照组。治疗组 16例 ,应用酚妥拉明联合甘利欣等综合治疗 ;对照组 14例 ,应用甘利欣等综合治疗 ,疗程为 1月。结果显示 ,治疗前两组的总胆红素 (TBil)、凝血酶原活动度 (PTA)的差异均无显著性 (P >0 0 5 )。治疗结束后 ,与对照组相比 ,治疗组TBil降低、PTA上升更明显 ,差异有显著意义 (P <0 0 5 ) ;治疗组和对照组TBil较治疗前均有明显下降(P <0 0 1,P <0 0 5 ) ,PTA明显上升 (P <0 0 1)。两组显效率、总有效率间的差异无显著性 (P >0 0 5 )。酚妥拉明联合甘利欣治疗慢性重型肝炎降低胆红素、提高凝血酶原活动度有较好的疗效Abstract: To observe the clinical efficacy of Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate in the treatment of chronic hepatitis gravis. 30 patients with chronic hepatitis gravis were randomly divided into treated group and control group. Treated group included 16 patients, treated by Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate, and control group included 14 patients, treated by Diammonium-Glycyrrhizinate. The two groups were given other composite treatments. The whole treatment lasted 1 month, the clinical efficacy was observed and the results were analysed by statistics. The results showed that there weren't difference in serum total bilirubin (STB) and prothrombin active (PTA) between the two groups before treatment (P>0.05) . At the end of treatment, STB was lower and PTA was higher in treated group compared with control group (P<0.05) . STB of the two groups were lower (P<0.01, P<0.05) and PTA were higher (P<0.01) after treatment. Treated group was improved in therapeutic efficacy. Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate has good clinical efficacy in the treatment of chronic hepatitis gravis.
-
[1]巫善明、高涛.胆汁郁积性肝炎的治疗[J].实用内科杂志, 1992, 12 (9) ∶460-461. [2]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324-329. [3]顾长海.重型病毒性肝炎的治疗问题[J].中国实用内科杂志, 1995, 15 (3) ∶145-147. [4]高寿征.病毒性肝炎防治研究[M].北京:北京出版社, 1993∶198. -
本文二维码
计量
- 文章访问数: 1904
- HTML全文浏览量: 19
- PDF下载量: 740
- 被引次数: 0
下载:
